💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ciprofloxacin

CHEMBL8 Phase 4 Đã phê duyệt Small molecule
Half-Life
4 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
331.3 g/mol
LogP
-1.1
Phase
4

A broad-spectrum fluoroquinolone, ciprofloxacin halts bacterial DNA replication by inhibiting the enzymes DNA gyrase and topoisomerase IV. It treats urinary and respiratory tract infections, typhoid fever, and certain gram-negative infections, and is stockpiled for anthrax prophylaxis. Marketed as Cipro and Ciloxan, it carries the formula C17H18FN3O3. Tendon rupture, peripheral neuropathy, and prolongation of the cardiac QT interval are recognized safety concerns that shape its use, and rising resistance has narrowed some of its former applications.

A broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication. It is used for a wide range of infections including urinary tract infections, respiratory infections, typhoid fever, and anthrax prophylaxis. Tendon rupture, peripheral neuropathy, and prolongation of the QT interval are important safety concerns.

Khối lượng phân tử

331,3460 g/mol

LogP

-1,10

TPSA

72,90 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Infectious Disease Urology

Phân loại thuốc

J — J - Antiinfectives for Systemic Use

Cơ chế tác dụng

Inhibits bacterial DNA gyrase and topoisomerase IV.

Pharmacokinetics (PK)

Half-Life 4 hours

Pharmacodynamics (PD)

Cơ chế

Inhibits bacterial DNA gyrase and topoisomerase IV.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O

                

                

                
                

                    
InChI

                    
InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H18FN3O3

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
Liên kết có thể quay

                        
3

                    

                    
                    
                    

                        
Nguyên tử nặng

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Ciprofloxacin + Ondansetron
                            
                        

                        
                        
Ciprofloxacin and ondansetron both prolong the QT interval; combined use raises the risk of torsades de pointes and sudden cardiac death.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ciprofloxacin + Quetiapine
                            
                        

                        
                        
Ciprofloxacin and quetiapine both prolong the QT interval and ciprofloxacin also increases quetiapine exposure via CYP3A4 inhibition.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Ciprofloxacin + Levothyroxine
                            
                        

                        
                        
Ciprofloxacin can reduce levothyroxine absorption through complex formation and potential effects on gut motility and transport, risking under-replacement in hypothyroid patients on long courses.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Ciprofloxacin + Warfarin
                            
                        

                        
                        
Ciprofloxacin consistently enhances warfarin's anticoagulant effect, raising INR and increasing the risk of bleeding complications.

                        
                    
                    
                    
                        

                            

  
  Major


                            
                                Ciprofloxacin + Azithromycin
                            
                        

                        
                        
Both azithromycin and ciprofloxacin prolong the QT interval; concurrent or overlapping use significantly increases torsades de pointes risk.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Câu hỏi thường gặp

                

                    
                    

                        
                        

                            
A broad-spectrum fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication. It is used for a wide range of infections including urinary tract infections, respiratory infections, typhoid fever, and anthrax prophylaxis. Tendon rupture, peripheral neuropathy, and prolongation of the QT interval are important safety concerns.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits bacterial DNA gyrase and topoisomerase IV.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Ciprofloxacin: Half-life: 4 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Ciprofloxacin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            
            

                
                
                    ADME Journey →
                
                
                
            

            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Amoxicillin
                            Small molecule
                        
                        
                        
                            Azithromycin
                            Small molecule
                        
                        
                        
                            Doxycycline
                            Small molecule
                        
                        
                        
                            Metronidazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL8.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2764.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tuyên bố miễn trách y tế

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.